Compare Ginkgo Bioworks Holdings Inc (DNA) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Under Armour Inc Class A — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Under Armour Inc Class A trades at $4.78 (market cap $2.07B). The key difference: Under Armour Inc Class A is far larger — about 2.7× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Under Armour Inc Class A for 18 Days on average.
| DNA | UA | |
|---|---|---|
Market Cap | $763.64M | $2.07B |
Volume | 3,204,177 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $15.83 | $7.88 |
52-Week Low | $5.48 | $3.96 |
Typical Hold Time | 7 Days | 18 Days |
Enterprise Value | $865.59M | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.
DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.
Under Armour (UA) trades at $4.78, up 1.7% with a bullish technical signal despite negative profitability metrics. The company reported mixed quarterly results with two beats and one miss, while revenue declined to $4.9B in 2026 with a net loss of $492M. Analyst consensus shows 40% buy ratings but sentiment remains cautious due to ongoing revenue challenges and negative cash flow trends.
The outlook remains challenging with declining revenue and persistent losses, though the stock's low P/S ratio of 0.41 offers valuation support. Key risks include weak North American demand and competitive pressures, while potential catalysts require successful execution of turnaround strategies to restore profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
